Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Gensei Kajiwara"'
Autor:
Naoki Nakamura, Hisashi Yoshimi, Gensei Kajiwara, Mutsumi Okamura, Kento Kawamura, Yumiko Nishimura, Naomi Tamaki, Shingo Dan, Nachi Namatame, Takao Yamori, Sho Isoyama
Publikováno v:
Cancer Science
Drug resistance often critically limits the efficacy of molecular targeted drugs. Although pharmacological inhibition of phosphatidylinositol 3-kinase (PI3K) is an attractive therapeutic strategy for cancer therapy, molecular determinants for efficac
Autor:
Tatsuro Irimura, Yumiko Nishimura, Shingo Dan, Takao Yamori, Naoki Nakamura, Mariko Seki, Sho Isoyama, Gensei Kajiwara
Publikováno v:
Cancer Sci
Acquired resistance is a major obstacle for conventional cancer chemotherapy, and also for some of the targeted therapies approved to date. Long‐term treatment using protein tyrosine kinase inhibitors (TKIs), such as gefitinib and imatinib, gives r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb543b59629f7be3d20792d8cabc522
https://europepmc.org/articles/PMC7659208/
https://europepmc.org/articles/PMC7659208/
Autor:
Hisashi Yoshimi, Okamura Mutsumi, Shingo Dan, Gensei Kajiwara, Naoki Nakamura, Takao Yamori, Sho Isoyama, Naomi Tamaki, Yumiko Nishimura
Publikováno v:
Molecular Cancer Therapeutics. 14:A43-A43
Drug resistance often critically limits the efficacy of molecular targeted drugs. Although pharmacological inhibition of phosphatidylinositol 3-kinase (PI3K) is an attractive therapeutic strategy for cancer therapy, molecular determinants for efficac
Autor:
Shingo Dan, Yumiko Nishimura, Naomi Tamaki, Takao Yamori, Sho Isoyama, Naoki Nakamura, Mutsumi Okamura, Gensei Kajiwara
Publikováno v:
Cancer Research. 73:4450-4450
The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in human cancers. Therefore PI3K is thought to be a promising target for cancer therapy, and many compounds targeting PI3K have been developed and tested in clinical trials. Acq